Dietary patterns derived by reduced rank regression are associated with lipid disorders among Korean adults: a cross-sectional analysis

[1] Tirronen A(2019)Recent advances in novel therapies for lipid disorders Hum Mol Genet 28 R49-R54

[2] Hokkanen K(2010)Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 1670-1681

[3] Vuorio T(2017)Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the Strong Heart Study Diabetes Care 40 529-537

[4] Ylä-Herttuala S(2022)Cardiovascular disease burden attributable to dietary risk factors from 1990 to 2019: a systematic analysis of the global burden of disease study Nutr Metab Cardiovasc Dis 32 897-907

[5] Baigent C(2020)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 41 111-188

[6] Blackwell L(2003)Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials Am J Clin Nutr 77 1146-1155

[7] Emberson J(2017)Clinical outcomes of dietary replacement of saturated fatty acids with unsaturated fat sources in adults with overweight and obesity: a systematic review and meta-analysis of randomized control trials Ann Nutr Metab 71 107-117

[8] Holland LE(2018)Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease Cochrane Database Syst Rev 7 Cd012345-1248

[9] Reith C(2008)Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia Expert Opin Pharmacother 9 1237-1071

[10] Bhala N(2012)Decreased plasma cholesterol concentrations after PUFA-rich diets are not due to reduced cholesterol absorption/synthesis Lipids 47 1063-1350

[1] Tirronen A(2019)Recent advances in novel therapies for lipid disorders Hum Mol Genet 28 R49-R54

[2] Hokkanen K(2010)Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 1670-1681

[3] Vuorio T(2017)Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the Strong Heart Study Diabetes Care 40 529-537

[4] Ylä-Herttuala S(2022)Cardiovascular disease burden attributable to dietary risk factors from 1990 to 2019: a systematic analysis of the global burden of disease study Nutr Metab Cardiovasc Dis 32 897-907

[5] Baigent C(2020)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 41 111-188

[6] Blackwell L(2003)Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials Am J Clin Nutr 77 1146-1155

[7] Emberson J(2017)Clinical outcomes of dietary replacement of saturated fatty acids with unsaturated fat sources in adults with overweight and obesity: a systematic review and meta-analysis of randomized control trials Ann Nutr Metab 71 107-117

[8] Holland LE(2018)Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease Cochrane Database Syst Rev 7 Cd012345-1248

[9] Reith C(2008)Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia Expert Opin Pharmacother 9 1237-1071

[10] Bhala N(2012)Decreased plasma cholesterol concentrations after PUFA-rich diets are not due to reduced cholesterol absorption/synthesis Lipids 47 1063-1350